Leveraged Commentary and Data’s (LCD) credit data, news, and research are now on PitchBook.
Learn more »
Kainos Medicine Overview
(As of Thursday Closing)
Kainos Medicine General Information
Developer of novel drugs intended to provide research and develop various medicines for cancers and brain and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is under phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is under phase II clinical study to treat HIV/AIDS, thereby providing healthcare companies and healthcare professionals with the various treatment for novel diseases such as brain diseases and cancers.